Literature DB >> 14996190

Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion.

Jean-Jacques Lefrère1, Robert Girot, François Lefrère, Nicolas Guillaume, Joelle Lerable, Nadine Le Marrec, Françoise Bouchardeau, Syria Laperche.   

Abstract

BACKGROUND: The disappearance of anti-HCV antibodies over time, after a self-limited infection, also referenced seroreversion, has been observed. The frequency of this phenomenon remains controversial, especially in immunocompetent subjects. However, it has important implications in the context of transfusion inquiries, in particular in case of a blood donor suspected to have transmitted HCV through a past blood donation. STUDY DESIGN AND METHODS: Our findings are presented of a longitudinal study, including 16 patients from a cohort of 78 immunocompetent, multitransfused individuals who were positive for anti-HCV (EIA and confirmatory assay [RIBA]) and followed over a long period of time without having received any antiviral therapy. The aim was to establish whether a past and self-resolved HCV infection could evolve toward a negative serology.
RESULTS: The 16 patients were classified in three groups: 1) 12 patients who remained anti-HCV positive with no evolution in their RIBA pattern after a mean follow-up of 7.6 years; 2) one patient who presented a complete seroreversion 6 years after enrollment; and 3) three patients with a partial seroreversion over a mean follow-up of 16 years.
CONCLUSION: HCV infection is not always characterized by a persistent antibody response, even in immunocompetent individuals. This should be taken into consideration when transfusion inquiries are conducted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996190     DOI: 10.1111/j.1537-2995.2004.00656.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  12 in total

1.  Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index.

Authors:  Edward L Murphy; Junyong Fang; Yongling Tu; Ritchard Cable; Christopher D Hillyer; Ronald Sacher; Darrell Triulzi; Jerome L Gottschall; Michael P Busch
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

2.  Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes.

Authors:  Michael P Busch; Krishna K Murthy; Steven H Kleinman; Dale F Hirschkorn; Belinda L Herring; Eric L Delwart; Vito Racanelli; Joo Chun Yoon; Barbara Rehermann; Harvey J Alter
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

3.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

4.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

5.  Hepatitis C Virus Genotype Analyses in Chronic Hepatitis C Patients and Individuals With Spontaneous Virus Clearance Using a Newly Developed Serotyping Assay.

Authors:  Ruifeng Yang; Xiqin Yang; Bingshui Xiu; Huiying Rao; Ran Fei; Wenli Guan; Yan Liu; Qian Wang; Xiaoyan Feng; Heqiu Zhang; Lai Wei
Journal:  J Clin Lab Anal       Date:  2016-06-13       Impact factor: 2.352

6.  Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.

Authors:  Eshan U Patel; Andrea L Cox; Shruti H Mehta; Denali Boon; Caroline E Mullis; Jacquie Astemborski; William O Osburn; Jeffrey Quinn; Andrew D Redd; Gregory D Kirk; David L Thomas; Thomas C Quinn; Oliver Laeyendecker
Journal:  J Infect Dis       Date:  2016-01-14       Impact factor: 5.226

7.  Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France.

Authors:  Pierre Cappy; Laure Boizeau; Daniel Candotti; Rémi Caparros; Quentin Lucas; Eliane Garrabe; Christophe Martinaud; Sophie Le Cam; Pierre Gallian; Pascal Morel; Josiane Pillonel; Syria Laperche
Journal:  Blood Transfus       Date:  2021-05-12       Impact factor: 3.443

8.  Hepatitis C virus in blood donors, Brazil.

Authors:  Kátia Luz Torres; Adriana Malheiro; Adriana Tateno; Tatiane Amabile de-Lima; Laura Patricia Viana-Maia; João Paulo Diniz-Pimentel; Márcia Poinho Encarnação-de-Morais; Christiane Santana de-Melo-Usui; Flavia de-Oliveira-Braga; Igor Araújo Ferreira-Silva; Felicien Vasquez; José Eduardo-Levi
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

9.  Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Marie-Pierre Ripault; Rami Moucari; Ana Carolina Cardoso; Nathalie Boyer; Nathalie Giuily; Corinne Castelnau; Michelle Pouteau; Tarik Asselah; Marie Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Liver Int       Date:  2008-12-09       Impact factor: 5.828

10.  Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections.

Authors:  Kelly E Coller; Michael G Berg; Matthew Frankel; Kenn Forberg; Rita Surani; Charles Y Chiu; John Hackett; George J Dawson
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.